参考文献/References:
[1] OPOKU-TEMENG C, MALACHOWA N, KOBAYASHI S D, et al. Innate host defense against Klebsiella pneumoniae and the outlook for development of immunotherapies[J]. Journal of Innate Immunity, 2022,14(3): 167-181.
[2] MACKENZIE F M, FORBES K J, DORAI-JOHN T,et al. Emergence of a carbapenem-resistant Klebsiella pneumoniae[J]. Lancet, 1997, 350(9080): 783.
[3] European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net)-annual epidemiological report 2020[Z]. Sweden： Stockholm, 2022.
[4] 胡付品, 郭燕, 朱德妹, 等. 2021 年CHINET 中国细菌耐药监测[J]. 中国感染与化疗杂志, 2022, 22（5）：521-530. HU Fupin, GUO Yan, ZHU Demei, et al. CHINET surveillance of antimicrobial resistance among the bacterial isolates in 2021[J]. Chinese Journal of Infection and Chemotherapy, 2022, 22(5): 521-530.
[5] 全国细菌耐药监测网. 全国细菌耐药监测网2014 ～ 2019 年耐碳青霉烯类肺炎克雷伯菌流行病学变迁[J]. 中国感染控制杂志, 2021, 20(2): 175-179. China Antimicrobial Resistance Surveillance. Epidemiological change in carbapenem-resistant Klebsiella pneumoniae: surveillance report from China Antimicrobial Resistance Surveillance in 2014 ～ 2019[J]. Chinese Journal of Infection Control, 2021, 20(2):175-179.
[6] 郑茂, 陈宗耀, 王登朝, 等. 耐碳青霉烯类肺炎克雷伯菌感染的临床特征及耐药机制研究[J]. 现代检验医学杂志, 2022, 37(4): 143-148. ZHENG Mao, CHEN Zongyao, WANG Dengchao, et al. Study on the clinical characteristics of carbapenemresistant Klebsiella pneumoniae infection and its resistance mechanisms[J]. Journal of Modern Laboratory Medicine, 2022, 37(4): 143-148.
[7] NI Lijia, ZHANG Zhixian, SHEN Rui, et al. Disinfection strategies for carbapenem-resistant Klebsiella pneumoniae in a healthcare facility[J].Antibiotics（Basel）, 2022, 11(6): 736.
[8] ARATO V, RASO M M, GASPERINI G, et al. Prophylaxis and treatment against Klebsiella pneumoniae: current insights on this emerging antimicrobial resistant global threat[J]. International Journal of Molecular Sciences, 2021, 22(8): 4042.
[9] 赵颖, 李茁, 张鹏, 等. 2014 ～ 2020 年陕西省人民医院耐碳青霉烯类肺炎克雷伯菌检出率与同期抗生素暴露及相关危险因素分析[J]. 现代检验医学杂志,2021, 36(6): 192-196. ZHAO Ying, LI Zhuo, ZHANG Peng, et al. Exploration of risk factors and the antimicrobial exposure associated with increased detection of carbapenem-resistant Klebsiella pneumoniae in Shaanxi Provincial People’s Hospital from 2014 to 2020[J]. Journal of Modern Laboratory Medicine, 2021, 36(6): 192-196.
[10] KARAISKOS I, GALANI I, PAPOUTSAKI V, et al. Carbapenemase producing Klebsiella pneumoniae:implication on future therapeutic strategies[J]. Expert Review of Anti-Infective Therapy, 2022, 20(1): 53-69.
[11] BOUZA E. The role of new carbapenem combinations in the treatment of multidrug-resistant gram-negative infections[J]. Journal of Antimicrobial Chemotherapy,2021, 76(Suppl 4): iv38-iv45.
[12] KARAKONSTANTIS S, KRITSOTAKIS E I, GIKAS A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems,aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems[J]. Infection, 2020, 48(6): 835-851.
[13] CASTANHEIRA M, DESHPANDE L M, MENDES R E, et al. Variations in the occurrence of resistance phenotypes and carbapenemase genes among Enterobacteriaceae isolates in 20 years of the SENTRY antimicrobial surveillance program[J]. Open Forum Infectious Diseases, 2019, 6(Suppl 1): S23-S33.
[14] TILAHUN M, KASSA Y, GEDEFIE A, et al. Emerging carbapenem-resistant Enterobacteriaceae infection, its epidemiology and novel treatment options: a review [J].Infection and Drug Resistance, 2021, 14: 4363-4374.
[15] PLAZAK M E, TAMMA P D, HEIL E L. The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria[J]. Expert Opinion on Pharmacotherapy, 2018,19(18): 2019-2031.
[16] 中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识编写组, 中国医药教育协会感染疾病专业委员会, 中华医学会细菌感染与耐药防控专业委员会.中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识[J]. 中华医学杂志, 2021, 101（36）：2850-2860. Expert Consensus Compilation Group on Diagnosis,Treatment and Prevention of Carbapenem-Resistant Enterobacteriaceae Bacterial, Infectious Diseases Society of China, Chinese Society of Bacterial Infection and Resistance. Treatment and prevention of carbapenem-resistant Enterobacteriaceae bacterial infections [J]. National Medical Journal of China, 2021,101(36): 2850-2860.
[17] 阿力米热·艾买提, 丁丽, 伊思达, 等. 耐碳青霉烯类肺炎克雷伯菌感染治疗进展[J]. 中国感染与化疗杂志, 2022, 22(6): 779-784. ALIMIRE Ameti, DING Li, YI Sida, et al. Carbapenemresistant Klebsiella pneumoniae infections: recent treatment advances[J]. Chinese Journal of Infection and Chemotherapy, 2022, 22(6): 779-784.
[18] HOU Siyuan, WU Dan, FENG Xinghuo. Polymyxin monotherapy versus polymyxin-based combination therapy against carbapenem-resistant Klebsiella pneumoniae: A systematic review and meta-analysis [J].Journal of Global Antimicrobial Resistance, 2020, 23:197-202.
[19] EMRE S, MOROLU C, YLDRMAK T ,et al. Combination antibiotic therapy in pan-resistant Klebsiella pneumoniae infection: A report of two cases[J].Klimik Dergisi, 2018, 31(2):169-172.
[20] SINGH M, KAUR L, BAJAJ R, et al. Double carbapenem regimen used as salvage therapy to treat multidrug-resistant Klebsiella pneumoniae causing ventilator-associated pneumonia[J]. Advances in Respiratory Medicine, 2021, 89(2): 203-206.
[21] ERDEM F, ABULAILA A, AKTAS Z, et al. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemaseproducing colistin-resistant Klebsiella pneumoniae strains[J]. Antimicrobial Resistance and Infection Control, 2020, 9(1): 70.
[22] ZHANEL G G, LAWRENCE C K, ADAM H, et al. Imipenem-relebactam and meropenem-vaborbactam:two novel carbapenem-β-lactamase inhibitor combinations[J]. Drugs, 2018, 78(1): 65-98.
[23] ELJAALY K, ALHARBI A, ALSHEHRI S, et al. Plazomicin: a novel aminoglycoside for the treatment of resistant gram-negative bacterial infections[J].Drugs, 2019, 79(3): 243-269.
[24] DE SOUZA C M, DA SILVA ? P, J?NIOR N G O, et al. Peptides as a therapeutic strategy against Klebsiella pneumoniae[J]. Trends in Pharmacological Sciences,2022, 43(4): 335-348.
[25] ZHANG Xiaodong, SHI Shiyi, YAO Zhuocheng,et al. Antimicrobial peptide WAM-1: a promising antibacterial and anti-inflammatory drug against carbapenem-resistant Klebsiella pneumoniae[J]. Journal of Antimicrobial Chemotherapy, 2022, 77(7): 1903-1911.
[26] VAN DER WEIDE H, VERMEULEN-DE JONGH D M C, VAN DER MEIJDEN A, et al. Antimicrobial activity of two novel antimicrobial peptides AA139 and SET-M33 against clinically and genotypically diverse Klebsiella pneumoniae isolates with differing antibiotic resistance profiles[J]. International Journal of Antimicrobial Agents, 2019, 54(2): 159-166.
[27] VAN DER WEIDE H, COSS?O U, GRACIA R, et al. Therapeutic efficacy of novel antimicrobial peptide AA139-nanomedicines in a multidrug-resistant Klebsiella pneumoniae pneumonia-septicemia model in rats[J]. Antimicrobial Agents and Chemotherapy, 2020,64(9): e00517-e00520.
[28] LYU W, MI Dehui, VINSON P N, et al. Large-scale identification of multiple classes of host defense peptide-inducing compounds for antimicrobial therapy[J]. International Journal of Molecular Sciences,2022, 23(15): 8400.
[29] WITHERELL K S, PRICE J, BANDARANAYAKE A D, et al. In vitro activity of antimicrobial peptide CDP-B11 alone and in combination with colistin against colistin-resistant and multidrug-resistant Escherichia coli[J]. Scientific Reports, 2021, 11(1):2151.
[30] WITHERELL KS, PRICE J, BANDARANAYAKE A D, et al. Circumventing colistin resistance by combining colistin and antimicrobial peptides to kill colistinresistant and multidrug-resistant gram-negative bacteria[J]. Journal of Global Antimicrobial Resistance, 2020,22: 706-712.
[31] BAKER K R, JANA B, HANSEN A M, et al. Repurposing azithromycin and rifampicin against gram-negative pathogens by combination with peptide potentiators[J]. International Journal of Antimicrobial Agents, 2019, 53(6): 868-872.
[32] AL-FARSI HM, AL-ADWANI S, AHMED S, et al. Effects of the antimicrobial peptide LL-37 and innate effector mechanisms in colistin-resistant Klebsiella pneumoniae with mgrb insertions [J]. Frontiers in Microbiology, 2019, 10: 2632.
[33] MUSILA L, TIRIA F R. A review of the innate immune evasion mechanisms and status of vaccine development of Klebsiella pneumonia[J]. Microbiology Research Journal International, 2021, 31(1): 33-47.
[34] BENGOECHEA J A, SA PESSOA J. Klebsiella pneumoniae infection biology: living to counteract host defences[J]. FEMS Microbiology Review, 2019, 43(2):123-144.
[35] CHOI M, TENNANT S M, SIMON R, et al. Progress towards the development of Klebsiella vaccines[J].Expert Review of Vaccines, 2019, 18(7): 681-691.
[36] ZHANG Baozhong, HU Danyu, DOU Ying, et al. Identification and evaluation of recombinant outer membrane proteins as vaccine candidates against Klebsiella pneumoniae [J]. Frontiers in Immunology,2021, 12: 730116.
[37] RODRIGUES M X, YANG Yongqiang, DE SOUZA MEIRA E B, et al. Development and evaluation of a new recombinant protein vaccine (YidR) against Klebsiella pneumoniae infection[J]. Vaccine, 2020,38(29): 4640-4648.
[38] DIAGO-NAVARRO E, MOTLEY M P, RUIZ-PER?Z G, et al. Novel, broadly reactive anticapsular antibodies against carbapenem-resistant Klebsiella pneumoniae protect from infection[J]. mBio, 2018, 9(2): e00091-18.
[39] BANERJEE K, MOTLEY M P, DIAGO-NAVARRO E,et al. Serum antibody responses against carbapenemresistant Klebsiella pneumoniae in infected patients[J].mSphere, 2021, 6(2): e01335-20.
[40] BRONCANO-LAVADO A, SANTAMAR?A-CORRAL G, ESTEBAN J, et al. Advances in bacteriophage therapy against relevant multi drug-resistant pathogens[J]. Antibiotics-Basel, 2021, 10(6): 672.
[41] 石鑫. 噬菌体治疗耐药肺炎克雷伯菌感染的临床应用和机制研究[D]. 上海：上海交通大学, 2019. SHI Xin. Clinical application and mechanism of phage therapy for drug-resistant Klebsiella pneumoniae infection[D]. Shanghai：Shanghai Jiaotong University,2019.
[42] CORBELLINO M, KIEFFER N, KUTATELADZE M, et al. Eradication of a multidrug-resistant,carbapenemase-producing Klebsiella pneumoniae isolate following oral and intra-rectal therapy with a custom made, lytic bacteriophage preparation[J].Clinical Infectious Diseases, 2020, 70(9): 1998-2001.
[43] CANO E J, CAFLISCH K M, BOLLYKY P L, et al. Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniae infection: case report and in vitro characterization of anti-biofilm activity[J].Clinical Infectious Diseases, 2021, 73(1): e144-e151.
[44] 高雅, 王兆飞, 严亚贤. 噬菌体治疗肺炎克雷伯菌感染的研究进展[J]. 微生物学通报, 2021, 48(9): 3271-3280. GAO Ya, WANG Zhaofei, YAN Yaxian. Advances in the treatment of Klebsiella pneumoniae infection with bacteriophage therapy[J]. Microbiology, 2021, 48(9):3271-3280.
[45] GU LIU C, GREEN S I, MIN L, et al. Phageantibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry[J].mBio, 2020, 11(4): e01462-20.
[46] VAREILLE-DELARBRE M, MIQUEL S, GARCIN S, et al. Immunomodulatory effects of lactobacillus plantarum on inflammatory response induced by Klebsiella pneumoniae[J]. Infection and immunity,2019, 87(11): e00570-19.
[47] IWANAGA N, SANDQUIST I, WANEK A, et al. Host immunology and rational immunotherapy for carbapenem-resistant Klebsiella pneumoniae infection[J]. JCI Insight, 2020, 5(8): e135591.
[48] FRAILE-?GREDA V, CA?ADAS O, WEAVER T E,et al. Synergistic action of antimicrobial lung proteins against Klebsiella pneumoniae[J]. International Journal of Molecular Sciences, 2021, 22(20): 11146.
[49] RANGASAMY T, GHIMIRE L, JIN Liliang, et al. Host defense against Klebsiella pneumoniae pneumonia is augmented by lung-derived mesenchymal stem cells[J].Journal of Immunology, 2021, 207(4): 1112-1127.
[50] REKHA R S, KARADOTTIR H, AHMED S, et al. Innate effector systems in primary human macrophages sensitize multidrug-resistant Klebsiella pneumoniae to antibiotics[J]. Infection and Immunity, 2020, 88(8):e00186-20.
[51] LIU Dong, CHEN Zhifu, YUAN Yue, et al. Innate immune effectors play essential roles in acute respiratory infection caused by Klebsiella pneumoniae[J]. J Immunol Res, 2020, 2020: 5291714.
相似文献/References:
[1]徐小红,巫之韵,蔡美莉,等.产酸克雷伯菌耐碳青霉烯类抗生素耐药机制的研究[J].现代检验医学杂志,2017,32(01):19.[doi:10.3969/j.issn.1671-7414.2017.01.006]
XU Xiao-hong,WU Zhi-yun,CAI Mei-li,et al.Study on the Resistance Mechanisms
of Carbapenem-Resistant Klebsiella Oxytoca[J].Journal of Modern Laboratory Medicine,2017,32(06):19.[doi:10.3969/j.issn.1671-7414.2017.01.006]
[2]程 莉,谭婷婷,魏红霞,等.临床分离的耐碳青霉烯肺炎克雷伯菌的耐药机制研究[J].现代检验医学杂志,2017,32(03):112.[doi:10.3969/j.issn.1671-7414.2017.03.030]
CHENG Li,TAN Ting-ting,WEI Hong-xia,et al.Resistance Mechanisms of Clinical Isolated
Carbapenem-Resistant Klebsiella Pneumoniae[J].Journal of Modern Laboratory Medicine,2017,32(06):112.[doi:10.3969/j.issn.1671-7414.2017.03.030]
[3]张 丽,齐 军,吴宗勇,等.耐碳青霉烯类肺炎克雷伯菌临床分离株中喹诺酮类及16SrRNA甲基化酶基因的检测[J].现代检验医学杂志,2018,33(05):27.[doi:10.3969/j.issn.1671-7414.2018.05.008]
ZHANG Li,QI Jun,WU Zong-yong,et al.Detection of Quinolone and 16SrRNA Methyltransferasegene of Clinical Isolated Carbapenem-Resistant Klebsiella Pneumoniae[J].Journal of Modern Laboratory Medicine,2018,33(06):27.[doi:10.3969/j.issn.1671-7414.2018.05.008]
[4]刘登科,牛虹博,葛正茂,等.曲霉菌对唑类药物的耐药机制最新研究进展[J].现代检验医学杂志,2020,35(02):161.[doi:10.3969 ／ j.issn.1671-7414.2020.02.044]
LIU Deng-ke,NIU Hong-bo,GE Zheng-mao,et al.Recent Advances in the Mechanism of Aspergillus Resistance to Azole Drugs[J].Journal of Modern Laboratory Medicine,2020,35(06):161.[doi:10.3969 ／ j.issn.1671-7414.2020.02.044]
[5]赵 颖,李 茁,张 鹏,等.2014~2020年陕西省人民医院耐碳青霉烯类肺炎克雷伯菌检出率与同期抗生素暴露及相关危险因素分析[J].现代检验医学杂志,2021,36(06):192.[doi:10.3969/j.issn.1671-7414.2021.06.042]
ZHAO Ying,LI Zhuo,ZHANG Peng,et al.Exploration of Risk Factors and the Antimicrobial Exposure Associated with Increased Detection of Carbapenem-resistant Klebsiella Pneumoniae in Shaanxi Provincial People’s Hospital from 2014 to 2020[J].Journal of Modern Laboratory Medicine,2021,36(06):192.[doi:10.3969/j.issn.1671-7414.2021.06.042]
[6]郑 茂a,陈宗耀a,王登朝a,等.耐碳青霉烯类肺炎克雷伯菌感染的临床特征及耐药机制研究[J].现代检验医学杂志,2022,37(04):143.[doi:10.3969/j.issn.1671-7414.2022.04.028]
ZHENG Maoa,CHEN Zong-yaoa,WANG Deng-chaoa,et al.Study on the Clinical Characteristics of Carbapenem-Resistant Klebsiella Pneumoniae Infection and Its Resistance Mechanisms[J].Journal of Modern Laboratory Medicine,2022,37(06):143.[doi:10.3969/j.issn.1671-7414.2022.04.028]
[7]雷 昕,李志兰,卢凌鹏,等.非编码RNA 在肝癌化疗耐药中的作用机制最新研究进展[J].现代检验医学杂志,2024,39(02):198.[doi:10.3969/j.issn.1671-7414.2024.02.036]
LEI Xin,LI Zhilan,LU Lingpeng,et al.Latest Research Progress of the Mechanism of Non-coding RNA in Chemoresistance of Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2024,39(06):198.[doi:10.3969/j.issn.1671-7414.2024.02.036]